Marketing
-
Out-of-pocket drug costs still murky, report underscores
A recent look at drug costs for patients from Iqvia suggests they have, on average, fallen. Whether that's partially because of discounts and rebates remains unclear.
By Jacob Bell • April 20, 2018
-
Tagrisso wins first-line lung cancer approval, boosting AstraZeneca
Securing the FDA OK is a key step in AstraZeneca's plan to turn Tagrisso into a multi-billion dollar drug franchise.
By Suzanne Elvidge • April 20, 2018
-
Lilly's baricitinib to face tough questions at AdComm
FDA staff reviewers raised doubts about the safety of the once-rejected rheumatoid arthritis drug ahead of an advisory committee meeting Monday.
By Lisa LaMotta • April 19, 2018
-
Cosentyx jitters weigh on Novartis
Worries over a slowdown in the immunology drug's sales and a sharp decline in the Swiss pharma's U.S. generics business overshadowed otherwise strong quarterly growth.
By Ned Pagliarulo • April 19, 2018
-
Pushing 'value,' Harvard Pilgrim tests outcomes deals
An agreement with AstraZeneca for the pharma's lung drug Symbicort is the ninth value-based contract publicly announced by the regional insurer.
By Ned Pagliarulo • April 18, 2018
-
Rigel secures FDA approval for rare disease drug
News of the OK helped shares in the biotech recover from the effect of a clinical setback earlier this month.
By Randi Hernandez • April 18, 2018
-
In win for generics makers, court knocks back Maryland price gouging law
Wording was a key concern for the court of appeals, as the law's text would have allowed it to unconstitutionally regulate interstate commerce.
By Jacob Bell • April 18, 2018
-
Ultragenyx gets thumbs up for first inherited rickets therapy
Crysvita's FDA approval for X-linked hypophosphatemia also hands Ultragenyx a Priority Review Voucher — a valuable asset in the pharma world.
By Suzanne Elvidge • April 18, 2018
-
Amazon reportedly drops plan to distribute drugs to hospitals
The report is not entirely unexpected. Amazon previously canceled a wholesaler application in Maine and has told other state regulators it does not intend to sell drugs.
By David Lim • April 17, 2018
-
Hanmi scraps lung cancer drug due to AstraZeneca rival, reports say
Olita showed promise but fizzled amid partnership and safety setbacks, and ultimately failed to compete with AstraZeneca's Tagrisso.
By Jacob Bell • April 13, 2018
-
ICER releases draft report on CGRP migraine drugs
The watchdog group's review says that Aimovig could only treat 16% of the population without affecting the healthcare budget.
By Suzanne Elvidge • April 13, 2018
-
PCSK9s appear to be meeting less payer resistance
A new report finds the nation's largest health plans ultimately denied 26% of claims for the cholesterol-lowering drugs in 2017 — a lower rate than before.
By Jacob Bell • April 12, 2018
-
Lawmaker questions HHS drug pricing appointee for industry ties
In an April 9 letter, Rep. Keith Ellison asked HHS Secretary Alex Azar to explain the rationale behind appointing a CVS and Pfizer veteran to senior advisor on drug pricing reform.
By Jacob Bell • April 11, 2018
-
Payments influence oncologist prescribing, JAMA study claims
An analysis of payments to more than 2,500 doctors suggests non-research related money paid by drugmakers can shape prescribing patterns.
By Randi Hernandez • April 11, 2018
-
CVS hands pharmacists tool to compare drug prices
Aiming to tamp down on out-of-pocket costs, CVS will roll out a new program designed to help retail pharmacists find the cheapest drug option for patients.
By Ned Pagliarulo • April 11, 2018
-
Clovis closes in on rival PARP drugs with latest approval
Rubraca is behind AstraZeneca's Lynparza and Tesaro's Zejula in terms of sales, but a new label expansion could strengthen the drug's competitive standing.
By Jacob Bell • April 06, 2018
-
Medicare to pay hundreds of thousands for CAR-T therapies
CMS will give hospitals outpatient reimbursements of about $400,000 for Gilead's Yescarta and $500,000 for Novartis' Kymriah.
By Jacob Bell • April 06, 2018
-
Lawmakers demand details on 1,400% price hike for cancer drug
While NextSource's lomustine is no longer under patent protection, the company is currently the only manufacturer of the drug.
By Randi Hernandez • April 04, 2018
-
NICE's first impression of Dupixent: It's not cost-effective
Sanofi and Regeneron's potential blockbuster doesn't meet the requirements to be "an acceptable use of NHS resources," the U.K. body found.
By Jacob Bell • April 04, 2018
-
Amgen's money-back offer on Repatha isn't all that meaningful, researchers find
A new study suggests Amgen's outcomes-based payment scheme would only marginally improve the cost-effectiveness of the PCSK9 drug.
By Ned Pagliarulo • April 04, 2018
-
Pharma turns to new pain options amid opioid crisis
In its latest spotlight, BioPharma Dive explores the drug industry's efforts to develop novel approaches to treat pain and deter abuse.
By Lisa LaMotta • April 04, 2018
-
PhRMA argues early notice of price hikes won't benefit patients
Letting insurers, distributors and PBMs know when a drug's price is about to increase, as some state laws aim to do, could encourage drug stockpiling and shortages, the trade group said.
By Jacob Bell • April 02, 2018
-
Walmart reportedly in early talks to acquire Humana
The companies already partner on Medicare Part D drug plans. But a deal could boost Humana's group market offerings to compete with other insurers, suggests one analyst.
By David Lim • April 02, 2018
-
Teva's 'skinny label' generic didn't cause infringement of GSK's patent, judge finds
The decision means Teva doesn't have to fork over $235 million in lost profits and royalties to its pharma rival, as a jury previously ruled.
By Jacob Bell • March 29, 2018
-
Teva launches generic version of Shire's top-selling internal medicine
Lialda sales are already waning due to competition from other copycats, and will likely fall further as this latest rollout takes its toll.
By Jacob Bell • March 28, 2018